Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Not all eczema drugs work the same under the hood. A new proteomic analysis from the JADE COMPARE trial found that abrocitinib (a JAK inhibitor) modulated a broader range of serum proteins than dupilumab (an anti-IL-4 antibody) in atopic dermatitis patients. The findings suggest these drugs differ significantly at the molecular level, opening the door to more personalized eczema treatment.
Not all eczema drugs work the same under the hood. A new exploratory proteomics analysis of the phase 3 JADE COMPARE trial found that abrocitinib (Cibinqo), a JAK1-selective inhibitor, produced broader and more significant changes in the serum proteome of atopic dermatitis (AD) patients compared to dupilumab (Dupixent), an anti-IL-4 monoclonal antibody. The findings were presented as a late-breaking study at the EADV 2026 Congress in Vienna.
While both drugs reduced key Th2 inflammatory markers, abrocitinib uniquely downregulated Th1 markers and a greater number of Th17 markers. The higher 200-mg dose of abrocitinib showed the most pronounced protein changes and stronger correlations with clinical disease activity scores (EASI), suggesting a dose-dependent effect. Researchers say these molecular differences could help define distinct AD phenotypes and guide more individualized therapy choices.
By the Numbers:
Why it matters: AD is a complex, heterogeneous disease, and understanding how different drug classes act at the molecular level could eventually help clinicians match patients to the therapy most likely to work for their specific disease profile.
